HK Stock Market Move | SBP GROUP (01177) rises nearly 3% as marketing applications for TQH2722 and TQB2102 are both accepted

SBP GROUP (01177) rose nearly 3%, up 1.94% as of press time, at HK$5.525, with a turnover of HK$104 million. On the news front, on September 16, SBP GROUP issued an announcement that the National Class 1 innovative drug TQH2722 injection "IL-4R monoclonal antibody," independently developed by the company's subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Chia Tai Tianqing), has submitted a new drug application to the Center for Drug Evaluation (CDE) of China's National Medical Products Administration and has been accepted, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults whose condition is poorly controlled by topical medications or who are unsuitable for topical treatment. The acceptance of this new drug application is based on the positive clinical results from the TQH2722-III-01 study. On the same day, SBP GROUP issued an announcement that the National Class 1 innovative drug TQB2102 injection "HER2 bispecific epitope dual-antibody ADC," independently developed by the company's subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Chia Tai Tianqing), has submitted a new drug application to the Center for Drug Evaluation (CDE) of China's National Medical Products Administration and has been accepted, for adult breast cancer patients with unresectable or metastatic HER2-low expression (IHC 1+ or IHC 2+/ISH-) who have not previously received chemotherapy in the recurrent or metastatic disease setting. Previously, this indication was included by the CDE as a breakthrough therapy designation.